ClinicalTrials.gg
RecruitingNCT05909059Updated Oct 14, 2026

CAR T-cell Therapy in Patients With Renal Dysfunction

A Phase 2 interventional study of Fludarabine and Cyclophosphamide in Non-hodgkin Lymphoma,B Cell, Multiple Myeloma and Acute Lymphoblastic Leukemia, Adult, sponsored by Northside Hospital, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Northside Hospital, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Updated Oct 14, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies testing fludarabine in Multiple Myeloma — 5 open to participants now, 12 under way, none of them phase 3. fludarabine · Multiple Myeloma.

Planned enrollment
67th of 109
20 · median 31
Started
2024
with 1 other
Phase 2
53 of 110
2 open now
Primary completion
2026-12
later than 4 of 11 live
Registered
105th of 110
by date
Lead sponsor
4 of 110
Northside Hospital, Inc.

Among the 110 studies testing fludarabine in Multiple Myeloma, this one is the 67th largest by planned enrollment of the 109 interventional ones that give a count, is one of 2 that started in 2024, is one of 53 in phase 2, reaches primary completion later than 4 of the 11 other live ones, and was the 105th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

5 of the 110 studies testing fludarabine in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing fludarabine in Multiple Myeloma, or all of them as a file.
02

Study summary

This is a prospective, descriptive study designed to assess the feasibility of administering CAR T therapy among patients with moderate to severe renal impairment using dose adjusted lymphodepleting chemotherapy.

03

Conditions studied

  • Non-hodgkin Lymphoma,B Cell
  • Multiple Myeloma
  • Acute Lymphoblastic Leukemia, Adult
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
  • Adequate bone marrow function to receive lymphodepleting chemotherapy
  • Renal function \</= 60mL/min/1.73m2
  • 0-2

Exclusion criteria

Exclusion Criteria:

  • Relative CNS disorders
  • Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
  • Use of therapeutic dose systemic (defined as >20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Moderate Renal Dysfunction

    Moderate renal dysfunction will receive a 20% dose reduction of fludarabine and no dose reduction for cyclophosphamide.

    Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Severe Renal Dysfunction

    Several renal dysfunction will receive a 40% dose reduction of fludarabine and no dose reduction for cyclophosphamide.

    Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Dialysis Participants

    Participants on dialysis will receive a 50% dose reduction of fludarabine and a 25% dose reduction of cyclophosphamide.

    Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • Received IV on Days -5 to -3 before CAR T cell therapy

  • Received IV on Days -5 to -3 before CAR T cell therapy

06

What researchers measure

Primary outcomes

  1. Occurrence of CRS

    Collection of maximum grade of CRS (based on CTCAE v5) and when this event occurs post CAR T cell therapy infusion

    Time frame: 90 days

  2. Occurrence of ICANS

    Collection of maximum grade of ICANs (based on CTCAE v5) and when this event occurs after CAR T cell therapy infusion

    Time frame: 90 days

  3. Occurrence of Cytopenias

    Collection of grade 3 or higher (based on CTCAE v5) cytopenias not resolved by Day 30 post CAR T cell infusion

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • Caitlin Guzowski
    Atlanta, Georgia 30342, United States
    Recruiting
    • Caitlin Guzowski, MBA, MHA · Contactcaitlin.guzowski@northside.com · 404-851-8523
    • H. Kent Holland, MD · Sub investigator
    • Asad Bashey, MD · Sub investigator
    • Lawrence E Morris, MD · Sub investigator
    • Scott Solomon, MD · Sub investigator
    • Melhem Solh, MD · Principal investigator
    • Lizamarie Bachier-Rodriguez, MD · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 25 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

Primary completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jun 18, 2023
StartActual
Nov 18, 2024
Primary completionEst.
Dec 31, 2026was Aug 2026
CompletionEst.
Aug 31, 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 31, 2026→Dec 31, 2026
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Aug 31, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05909059
Lead sponsor
Northside Hospital, Inc.
Collaborators
Blood and Marrow Transplant Group of Georgia
Responsible party
Sponsor
First posted
Jun 18, 2023
Start date
Nov 18, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

Melhem Solh, MD
Contact
msolh@bmtga.com
404-255-1930
Caitlin Guzowski, MBA, MHA
Contact
caitlin.guzowski@northside.com
404-851-8523

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide

Start the discussion